Universität Münster
45
16
19
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
2.2%
1 terminated/withdrawn out of 45 trials
94.1%
+7.6% vs industry average
20%
9 trials in Phase 3/4
6%
1 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury
Role: lead
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
Role: lead
Liquid Biopsy in Paraneoplastic Neurological Syndromes
Role: collaborator
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Role: lead
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Role: collaborator
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Role: lead
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Role: lead
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Role: collaborator
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Role: collaborator
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Role: collaborator
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
Role: lead
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Role: collaborator
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Role: lead
tTF-NGR Randomized Study - STS
Role: lead
Multimodal Intervention for Painful Diabetic Neuropathy: NeuOst Feasibility Trial
Role: collaborator
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Role: lead
Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery
Role: lead
Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury
Role: lead
Remote Ischemic Preconditioning in Septic Patients
Role: lead
ESGE-Quality Improvement in Endoscopy: ERCP
Role: lead